Antiplatelet therapy in carotid artery stenting and carotid endarterectomy in the asymptomatic carotid surgery trial-2

Huibers, A; Halliday, A; Bulbulia, R; Coppi, G; De Borst, G

Journal article

Antiplatelet therapy in carotid artery stenting and carotid endarterectomy in the asymptomatic carotid surgery trial-2

Abstract:: Objective

Strokes are infrequent but potentially serious complications following carotid intervention, but antiplatelet therapy can reduce these risks. There are currently no specific guidelines on dose or duration of periprocedural antiplatelet treatment for patients undergoing carotid intervention. Within the ongoing Asymptomatic Carotid Surgery Trial-2 (ACST-2), this study aimed at assessing the current use of antiplatelet therapy before, during, and after CEA and CAS in patients with asymptomatic carotid stenosis.

Methods

Questionnaires were sent to ACST-2 collaborators seeking information about the use of antiplatelet therapy during the pre-, peri-, and post-operative periods in patients undergoing carotid intervention at 77 participating sites and also whether sites tested for antiplatelet therapy resistance.

Results

The response rate was 68/77 (88%). For CAS, 82% of sites used dual antiplatelet therapy (DAPT) preoperatively and 86% post-operatively with a mean post-procedural duration of 3 months (range 1e12), while 9% continued DAPT life-long. For CEA only 31% used DAPT pre-operatively, 24% post-operatively with a mean postprocedural duration of 3 months (range 1e5), while 10% continued DAPT life-long. For those prescribing postprocedural mono antiplatelet (MAPT) therapy (76%), aspirin was more commonly prescribed (59%) than clopidogrel (6%) and 11% of centres did not show a preference for either aspirin or clopidogrel. Eleven centres (16%) tested for antiplatelet therapy resistance.

Conclusion

There appears to be broad agreement on the use of antiplatelet therapy in ACST-2 patients undergoing carotid artery stenting and surgery. Although evidence to help guide the duration of peri-procedural antiplatelet therapy is limited, long-term treatment with DAPT appears similar between both treatment arms.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Huibers, A., Halliday, A., Bulbulia, R., Coppi, G., & De Borst, G. (2015). Antiplatelet therapy in carotid artery stenting and carotid endarterectomy in the asymptomatic carotid surgery trial-2. European Journal of Vascular and Endovascular Surgery, 51(3), 336–342.

MLA Style

Huibers, A, et al. “Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2.” European Journal of Vascular and Endovascular Surgery, vol. 51, no. 3, 2015, pp. 336–42.

Chicago Style

Huibers, A, A Halliday, R Bulbulia, G Coppi, and G De Borst. 2015. “Antiplatelet Therapy in Carotid Artery Stenting and Carotid Endarterectomy in the Asymptomatic Carotid Surgery Trial-2.” European Journal of Vascular and Endovascular Surgery 51 (3): 336–42.
Print